Anaprazole

Xuanzhu Biopharm set for spin-off in Hong Kong IPO

Xuanzhu Biopharm set for spin-off in Hong Kong IPO

The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines Key Takeaways: Xuanzhu…
0460.HK

Recent Articles

RELATED ARTICLES

  1. This pharmaceutical company posted an 11% rise in half-year revenue, helped by growing income from innovative medicines, as it pivots away from the generic drug business.
    Novel drugs lift Sino Biopharm earnings, easing price-cap pain
    1177.HK
  2. CSPC Pharma weighs up diet drug for bigger bottom line
    1093.HK
  3. Sichuan Biokin chases Hong Kong listing after BSM drug deal
  4. TransThera seeks Hong Kong IPO to sustain cancer drug research
  5. Akeso marks profit milestone with swift rights issue
    9926.HK
  6. InSilico seeks IPO boost to get AI drugs over the line
  7. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva